MET and glioblastoma: Bevacizumab-resistant glioblastomas present with increased MET phosphorylation and increased phosphorylation of MET-activated focal adhesion kinase and STAT3, which suggests a role for MET in features associated with anti-angiogenic therapy resistance both in vitro and in vivo [91].